prurigo nodularis
News/ News/ Sales and Marketing
FDA grants speedy review to Dupixent rare skin disease
Phil Taylor
dermatology, Dupixent, prurigo nodularis, rare disease, Regeneron, regulatory, Sanofi
0 Comment
X
FDA grants speedy review to Dupixent rare skin disease
https://pharmaphorum.com/news/fda-grants-speedy-review-to-dupixent-rare-skin-disease/
Dupixent scores a first in rare skin disease prurigo nodularis
Phil Taylor
dermatology, Dupixent, immunology, prurigo nodularis, rare disease, Regeneron, Sanofi
0 Comment
X
Dupixent scores a first in rare skin disease prurigo nodularis
https://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/